Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 19,532 | 10,552 | 5,755 | 28,378 | 45,686 |
| TOTAL | $21,082 | $13,926 | $10,208 | $36,022 | $46,002 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $21,082 | $13,926 | $10,208 | $36,022 | $46,002 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,591 | 2,306 | 1,293 | 3,961 | 688 |
| Accrued Expenses | 1,045 | 1,575 | 2,986 | 3,737 | 818 |
| TOTAL | $3,635 | $3,881 | $4,279 | $7,699 | $1,507 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 595 | 737 | 13,680 | 0 | 0 |
| TOTAL | $595 | $737 | $13,680 | $N/A | $N/A |
| Total Liabilities | $4,230 | $4,618 | $17,959 | $7,699 | $1,507 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,355 | 19,486 | 11,011 | 8,217 | 8,164 |
| Common Shares | 3 | 1 | 1 | 1 | 1 |
| Retained earnings | -163,704 | -134,850 | -110,259 | -54,055 | -28,726 |
| TOTAL | $16,851 | $9,308 | $-7,751 | $28,324 | $44,495 |
| Total Liabilities And Equity | $21,082 | $13,926 | $10,208 | $36,022 | $46,002 |